These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 34909720)

  • 21. Characteristics of Patients with Psoriasis Treated with Apremilast in the Corrona Psoriasis Registry.
    Gottlieb AB; Merola JF; Cirulli J; Williams CC; Linowski GJ; Paris M; Litman HJ; Guo N; Emeanuru K; McLean RR; Cronin A; Strober B
    Dermatol Ther (Heidelb); 2021 Feb; 11(1):253-263. PubMed ID: 33475970
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risankizumab for the Treatment of Moderate-to-Severe Psoriasis: Real-Life Multicenter Experience from the Czech Republic.
    Gkalpakiotis S; Cetkovska P; Arenberger P; Dolezal T; Arenbergerova M; Velackova B; Fialova J; Kojanova M;
    Dermatol Ther (Heidelb); 2021 Aug; 11(4):1345-1355. PubMed ID: 34089479
    [TBL] [Abstract][Full Text] [Related]  

  • 23. US real-world effectiveness of secukinumab for the treatment of psoriasis: 6-month analysis from the Corrona Psoriasis Registry.
    Strober BE; Germino R; Guana A; Greenberg JD; Litman HJ; Guo N; Lebwohl M
    J Dermatolog Treat; 2020 Jun; 31(4):333-341. PubMed ID: 31035822
    [No Abstract]   [Full Text] [Related]  

  • 24. Hydroids (Cnidaria, Hydrozoa) from Mauritanian Coral Mounds.
    Gil M; Ramil F; AgÍs JA
    Zootaxa; 2020 Nov; 4878(3):zootaxa.4878.3.2. PubMed ID: 33311142
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination Use of Systemic Therapies in Psoriasis: Baseline Characteristics from the Corrona Psoriasis Registry.
    Bonomo L; Abittan BJ; Hashim PW; Karki C; Mason M; Lebwohl M
    J Drugs Dermatol; 2019 Aug; 18(8):731-740. PubMed ID: 31424705
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.
    Blauvelt A; Papp K; Gottlieb A; Jarell A; Reich K; Maari C; Gordon KB; Ferris LK; Langley RG; Tada Y; Lima RG; Elmaraghy H; Gallo G; Renda L; Park SY; Burge R; Bagel J;
    Br J Dermatol; 2020 Jun; 182(6):1348-1358. PubMed ID: 31887225
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis.
    Lebwohl MG; Kircik L; Callis Duffin K; Pariser D; Hooper M; Wenkert D; Thompson EH; Yang J; Kricorian G; Koo J
    J Am Acad Dermatol; 2013 Sep; 69(3):385-92. PubMed ID: 23643256
    [TBL] [Abstract][Full Text] [Related]  

  • 28. IL-1β, IL-17A and combined phototherapy predicts higher while previous systemic biologic treatment predicts lower treatment response to etanercept in psoriasis patients.
    Liu Y; Qin G; Meng Z; Du T; Wang X; Tang Y; Cao J
    Inflammopharmacology; 2019 Feb; 27(1):57-66. PubMed ID: 30242748
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: a randomized controlled prospective trial.
    Al-Mutairi N; Nour T
    Expert Opin Biol Ther; 2014 Jun; 14(6):749-56. PubMed ID: 24661040
    [TBL] [Abstract][Full Text] [Related]  

  • 30. When IL-17 inhibitors fail: Real-life evidence to switch from secukinumab to adalimumab or ustekinumab.
    Damiani G; Conic RRZ; de Vita V; Costanzo A; Regazzini R; Pigatto PDM; Bragazzi NL; Pacifico A; Malagoli P
    Dermatol Ther; 2019 Mar; 32(2):e12793. PubMed ID: 30515970
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
    Spuls PI; Hooft L
    Br J Dermatol; 2012 Oct; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Product of the Physician Global Assessment and body surface area: a simple static measure of psoriasis severity in a longitudinal cohort.
    Walsh JA; McFadden M; Woodcock J; Clegg DO; Helliwell P; Dommasch E; Gelfand JM; Krueger GG; Duffin KC
    J Am Acad Dermatol; 2013 Dec; 69(6):931-7. PubMed ID: 24054760
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral surgeons in geographic regions and selected metropolitan areas.
    Graham JW
    J Oral Surg; 1979 Apr; 37 Spec No A():A50-64. PubMed ID: 285252
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Where you live matters: Regional differences in health care resource use for psoriasis in the United States.
    Nguyen KB; Read C; Wu KK; Armstrong AW
    J Am Acad Dermatol; 2020 Jun; 82(6):1360-1367. PubMed ID: 31606478
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR]).
    Strober BE; Bissonnette R; Fiorentino D; Kimball AB; Naldi L; Shear NH; Goyal K; Fakharzadeh S; Calabro S; Langholff W; You Y; Galindo C; Lee S; Lebwohl MG
    J Am Acad Dermatol; 2016 May; 74(5):851-61.e4. PubMed ID: 26853180
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association Between Quality of Life and Improvement in Psoriasis Severity and Extent in Pediatric Patients.
    Bruins FM; Bronckers IMGJ; Groenewoud HMM; van de Kerkhof PCM; de Jong EMGJ; Seyger MMB
    JAMA Dermatol; 2020 Jan; 156(1):72-78. PubMed ID: 31774449
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study.
    Papp KA; Langley RG; Sigurgeirsson B; Abe M; Baker DR; Konno P; Haemmerle S; Thurston HJ; Papavassilis C; Richards HB
    Br J Dermatol; 2013 Feb; 168(2):412-21. PubMed ID: 23106107
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Change in body weight and body mass index in psoriasis patients receiving biologics: A systematic review and network meta-analysis.
    Wu MY; Yu CL; Yang SJ; Chi CC
    J Am Acad Dermatol; 2020 Jan; 82(1):101-109. PubMed ID: 31400455
    [TBL] [Abstract][Full Text] [Related]  

  • 39. IL-17A in the Psoriatic Patients' Serum and Plaque Scales as Potential Marker of the Diseases Severity and Obesity.
    Michalak-Stoma A; Bartosińska J; Kowal M; Raczkiewicz D; Krasowska D; Chodorowska G
    Mediators Inflamm; 2020; 2020():7420823. PubMed ID: 32587472
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Real-world data from a single Greek centre on the use of secukinumab in plaque psoriasis: effectiveness, safety, drug survival, and identification of patients that sustain optimal response.
    Rompoti N; Sidiropoulou P; Panagakis P; Stratigos A; Papoutsaki M; Stefanaki E; Vavouli C; Politou M; Befon A; Kostakis P; Rigopoulos D; Nicolaidou E
    J Eur Acad Dermatol Venereol; 2020 Jun; 34(6):1240-1247. PubMed ID: 31953892
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.